Skip to main content
Premium Trial:

Request an Annual Quote

Oxford Nanopore Expands Agreement with University of Oxford


Oxford Nanopore Technologies said this week that it has signed a new agreement with the University of Oxford that will further strengthen its ties with its scientific co-founder, Hagan Bayley, a professor at Oxford.

Under the new agreement, which has an undisclosed duration, the company will provide an undisclosed amount of funding to support research in Bayley's group and will partner exclusively with the university to develop "revolutionary products for molecular analysis" based on discoveries made by the group.

Research projects in Bayley's group include the development of methods for direct sequencing of single-stranded DNA. The team receives funding under the National Human Genome Research Institute's "$1,000 Genome" grant program (see other article, this week).

Oxford Nanopore has already collaborated with Bayley's group extensively under a previous agreement.

According to an Oxford Nanopore spokesperson, the new agreement differs from the old one in that it now includes a "broad range of nanopore sensing discoveries" from Bayley's laboratory. The previous agreement, she said, was structured around specific projects.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.